News
-
-
PRESS RELEASE
Bioversys reports corporate highlights and key financials for the first half 2025
BioVersys AG reports key financials and corporate highlights for the first half of 2025, including successful Phase 2 outcomes: BV100 Phase 3 on track, Alpibectir Phase 2 with GSK, BV500 collaboration with Shionogi, improved FY 2025 guidance -
-
-
-
PRESS RELEASE
BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis
BioVersys receives EMA Orphan Designation for the combination of alpibectir and ethionamide for the treatment of tuberculosis. The designation provides key incentives for addressing drug resistance in TB treatment -
-
PRESS RELEASE
BIOVERSYS AND SHIONOGI ENTER INTO GLOBAL RESEARCH COLLABORATION FOR BROAD-SPECTRUM NON-TUBERCULOUS MYCOBACTERIA (NTM) CLINICAL CANDIDATE
BioVersys and Shionogi enter global research collaboration for NTM clinical candidate. BioVersys grants Shionogi license option for leads from BV500 program -
-
